Significant reduction in XXXX -resistant @entity794 ventilator-associated @entity55 associated with the institution of a prevention protocol.

@entity1 @entity3256 @entity1216 @entity55 @entity794 @entity23782 @entity221
OBJECTIVE: To determine whether the institution of a @entity3256 -resistant @entity794 prevention protocol was associated with a decrease in @entity3256 -resistant @entity794 ventilator-associated @entity55 in long-term, acute care ventilator @entity1 . DESIGN: A retrospective chart review comparing the number of episodes of clinical @entity55 per @entity1 ventilator day in the 12 months preceding and 24 months following the introduction of the protocol. SETTING: University affiliated, long-term, acute care ventilator hospital. @entity1 : Long-term, acute care ventilated @entity1 who presented with clinical @entity55 . INTERVENTIONS: Addition of a @entity3256 -resistant @entity794 prevention protocol. In addition to universal precautions, the protocol consisted of @entity23782 2% ointment applied to the anterior nares, and whole body washing with @entity1216 . All @entity1 were given @entity23782 and @entity1216 twice weekly. @entity1 were cohorted in the same room if they were, or had been, infected or colonized with @entity3256 -resistant @entity794 in any anatomical location or at any time. This procedure replaced strict isolation of @entity3256 -resistant @entity794 -infected or colonized individuals. MEASUREMENTS AND MAIN RESULTS: Clinical @entity55 was diagnosed when a @entity1 developed @entity221 , bronchorrhea, increased white blood cell count, @entity3256 -resistant @entity794 isolated from the tracheal aspirate, and new or increasing infiltrate on chest roentgenograph. During the 12 months preceding the protocol, there were 0.2% episodes of @entity3256 -resistant @entity794 ventilator-associated @entity55 per ventilated @entity1 day compared with 0.026% in the 24 months after the protocol (p < .001). The relative and absolute risk reductions associated with the introduction of the protocol were 87% and 6, respectively. CONCLUSIONS: The period following the institution of the protocol showed a significant reduction in episodes of clinical @entity55 compared with the 12-month period preceding the use of the protocol (p < .001). Thus, we conclude that the introduction of this protocol is associated with a significant decrease in @entity3256 -resistant @entity794 ventilator-associated @entity55 .
